Avalo Therapeutics appoints former ChemoCentryx CMO Rita Jain to board

Avalo Therapeutics, Inc.

Dr. Rita Jain appointed to Avalo's Board of Directors effective June 17, 2025.
She previously served as EVP and CMO at ChemoCentryx, advancing Tavneos for ANCA vasculitis.
Received initial non-qualified stock option for 40,200 shares, vesting over three years.
Board also adopted Amended Non-Employee Director Compensation Plan to attract qualified directors.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rita Jain

Director

AVTX · Avalo Therapeutics, Inc.

Effective: 2025-06-17
Filed: June 18, 2025, 7:59 PM ET

On June 17, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Rita Jain, M.D. to the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rita Jain was appointed as Director at Avalo Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On June 17, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Rita Jain, M.D. to the Board, effective immediately.

View on SEC.gov

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-032011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.